CLINICAL STUDY: ELECTROPHYSIOLOGY
Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide
A placebo-controlled, implantable cardioverter-defibrillator-based evaluation
Alexander Mazur, MD*,
Mark E. Anderson, MD, PhD*,
Sharon Bonney, MD and
Dan M. Roden, MD, FACC*
* Departments of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Pfizer Central Research, Groton, Connecticut, USA
Manuscript received July 26, 2000;
revised manuscript received October 16, 2000,
accepted December 13, 2000.
Reprint requests and correspondence: Dr. Dan M. Roden, Division of Clinical Pharmacology, Vanderbilt University, 532C Medical Research Building I, 23rd Avenue South at Pierce Avenue, Nashville, Tennessee 37232-6602
dan.roden{at}mcmail.vanderbilt.edu
OBJECTIVES
To compare the incidence of pause-dependent polymorphic ventricular tachycardia (PVT) in patients with implantable cardioverter-defibrillators (ICDs) randomly assigned to the QT-prolonging antiarrhythmic dofetilide or placebo.
BACKGROUND
Drug-related torsade de pointes (TdP) is usually recognized within days of initiating therapy, but its incidence during long-term therapy is unknown.
METHODS
We assessed the frequency of TdP and ICD electrograms compatible with TdP in a multicenter study that randomized ICD patients to placebo (n = 87) or dofetilide (n = 87). As reported elsewhere, the number of patients with a primary trial end point (ICD intervention for VT or ventricular fibrillation) was similar in the two groups. For this analysis, a qualifying event was TdP (on electrocardiogram) or an intracardiac electrogram showing pause-dependent PVT.
RESULTS
A total of 620 electrograms obtained in 131 patients were analyzed blindly by prospectively defined criteria for episodes of pause-dependent polymorphic VT. These were identified in 15/87 (17%) patients receiving dofetilide and 5/87 (6%) patients on placebo (p < 0.05). Five of these episodes were early (<3 days), all of which were TdP on dofetilide. There were 15 late events, 10 on dofetilide and five on placebo (p = 0.29). The median time to a late event was 22 days (range 6 to 107 days) for dofetilide and 99 days (range 34 to 207 days) for placebo.
CONCLUSIONS
Pause-dependent PVT was more common among patients receiving dofetilide, although total VT incidence was similar in the two groups. These data suggest that in ICD patients either long-term dofetilide therapy is associated with an increased risk of TdP or the drug alters VT morphology.
|
Abbreviations and Acronyms
| | ICD | = implantable cardioverter-defibrillator | | MVT | = monomorphic ventricular tachycardia | | PVT | = polymorphic ventricular tachycardia | | TdP | = torsade de pointes | | VF | = ventricular fibrillation | | VT | = ventricular tachycardia |
|
This article has been cited by other articles:
|
|
|
|
 
V. Y. Reddy, M. R. Reynolds, P. Neuzil, A. W. Richardson, M. Taborsky, K. Jongnarangsin, S. Kralovec, L. Sediva, J. N. Ruskin, and M. E. Josephson
Prophylactic Catheter Ablation for the Prevention of Defibrillator Therapy
N. Engl. J. Med.,
December 27, 2007;
357(26):
2657 - 2665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Mykytsey, J. L. Bauman, M. Razminia, T. Zheutlin, T. Wang, M. Saleem, S. Leal, and R. F. Kehoe
Observations on the Safety and Effectiveness of Dofetilide in Patients With Paroxysmal Atrial Fibrillation and Normal Left Ventricular Function
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2007;
12(1):
36 - 43.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. Haverkamp
Electrical storm: still a cryptogenic phenomenon?
Eur. Heart J.,
December 2, 2006;
27(24):
2921 - 2922.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Christ and U. Ravens
Do we need new antiarrhythmic compounds in the era of implantable cardiac devices and percutaneous ablation?
Cardiovasc Res,
December 1, 2005;
68(3):
341 - 343.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Falk
Rate Control Is Preferable to Rhythm Control in the Majority of Patients With Atrial Fibrillation
Circulation,
June 14, 2005;
111(23):
3141 - 3150.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Saoudi, J.P. Rinaldi, K. Yaici, and M. Bergonzi
Dofetilide: what role in the treatment of ventricular tachyarrhythmias?
Eur. Heart J.,
December 1, 2001;
22(23):
2141 - 2143.
[PDF]
|
|
|
|
|
|
|
M. R. Lauer
Dofetilide: is the treatment worse than the disease?
J. Am. Coll. Cardiol.,
March 15, 2001;
37(4):
1106 - 1110.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O. Kozhevnikov, K. Yamamoto, D. Robotis, M. Restivo, and N. El-Sherif
Electrophysiological Mechanism of Enhanced Susceptibility of Hypertrophied Heart to Acquired Torsade de Pointes Arrhythmias: Tridimensional Mapping of Activation and Recovery Patterns
Circulation,
March 5, 2002;
105(9):
1128 - 1134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
